Last reviewed · How we verify
Dose reduction concurrent chemotherapy
Dose reduction concurrent chemotherapy is a treatment strategy that lowers chemotherapy doses while administering them alongside other therapeutic modalities to improve tolerability.
Dose reduction concurrent chemotherapy is a treatment strategy that lowers chemotherapy doses while administering them alongside other therapeutic modalities to improve tolerability. Used for Cancer treatment with concurrent chemotherapy and radiation or other modalities.
At a glance
| Generic name | Dose reduction concurrent chemotherapy |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach involves reducing the standard chemotherapy dosage during concurrent administration with other treatments (such as radiation therapy or targeted agents) to minimize cumulative toxicity and adverse effects while maintaining therapeutic efficacy. The rationale is that concurrent modalities may have synergistic effects, allowing lower individual drug doses to achieve comparable outcomes with improved safety profiles.
Approved indications
- Cancer treatment with concurrent chemotherapy and radiation or other modalities
Common side effects
- Hematologic toxicity
- Gastrointestinal toxicity
- Mucositis
- Fatigue
Key clinical trials
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (PHASE3)
- TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck (NA)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
- A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: